These are promising results, especially point 1, which shows...

These are promising results, especially point 1, which shows patients receiving the combination therapy had an average survival time that was about 32% greater than those receiving chemotherapy alone.

The study investigates the effectiveness of combining standard chemotherapy with endoscopic ultrasound (EUS)-guided phosphorus-32 (^32P) microparticle intra-tumoral implantation in patients with locally advanced pancreatic cancer (LAPC). The researchers aimed to compare this combination therapy with standard chemotherapy alone using a propensity-score weighted analysis (PSWA) to reduce selection bias.

Key Findings:

1. Overall Survival Improvement:

   • The combination therapy group had a significantly longer restricted mean survival time (RMST) within 24 months after chemotherapy initiation. Specifically, an estimated 112 days longer than the chemotherapy-only group (459 days vs. 347 days).

2. Enhanced Local Progression-Free Time:

   • Patients receiving the combined treatment experienced an extended local progression-free time by an estimated 112 days compared to those on standard chemotherapy alone.

3. Higher Probability of Tumor Downstaging:

   • There was a 22.3% higher probability of tumor downstaging in the combination therapy group, suggesting better disease control.

4. Increased Tumor Vascularity:

   • Contrast-enhanced EUS (CE-EUS) assessments showed a significant increase in intra-tumoral vascularity at 4 and 12 weeks post-^32P implantation. This suggests that the combined treatment may enhance the delivery of chemotherapy agents to the tumor by improving microvascular flow.